Partnerships, Licensing, Investments and M&A Deals and Trends for 2015 in Pharmaceuticals

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$3500

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for 2015 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in 2015. The report portrays detailed comparative data on the number of deals and their value in the last five years, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry. Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

• Analysis of the market trends for the pharmaceutical industry in the global arena.

• Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

• Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

• Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

• Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

• Analysis of partnership and licensing deals based on clinical stage of development of products.

• Summary of the pharmaceutical deals globally in the last five years.

• Information on the top deals happened in the pharmaceutical industry.

• Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

• League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to Buy

Enhance your decision making capability in a more rapid and time sensitive manner.

Find out the major deal performing segments for investments in your industry.

Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

Identify companies that are aggressively looking to raise capital in the market

Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

Identify growth segments and opportunities in each region within the industry.

Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1Table of Contents

1Table of Contents2

1.1List of Tables7

1.2List of Figures12

2Pharmaceutical & Healthcare, Global, Deals Summary18

2.1Pharmaceutical & Healthcare, Global, Deals Analysis, 201518

2.1.1Pharmaceuticals & Healthcare, Global, Deals Analysis, 2015 by Quarter20

2.2Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, 201522

2.3Pharmaceuticals & Healthcare, Global, by Type, Deal Values, 201523

2.4Pharmaceuticals & Healthcare, Global, Top Deals, 201524

2.5Pharmaceuticals & Healthcare, Top Deals, Global, Summaries, 201525

2.5.1Allergan and Pfizer to Combine in USD160 Billion Deal25

2.5.2Teva Pharma to Acquire Generics Drug Business from Allergan for USD40.5 Billion26

2.5.3Actavis Raises USD21 Billion in Public Offering of Senior Notes27

2.5.4AbbVie Acquires Pharmacyclics28

2.5.5Pfizer Acquires Hospira for USD17 Billion29

2.5.6Danaher Acquires Pall for USD13.8 Billion30

2.5.7CVS Health Acquires Omnicare for USD12.9 Billion31

2.5.8UnitedHealth Acquires Catamaran for USD12.8 Billion32

2.5.9Valeant Pharma Acquires Salix Pharma for USD10.9 Billion32

2.5.10AbbVie Raises USD16.7 Billion in Public Offering of Notes34

3Pharmaceuticals & Healthcare, Global, Top Deal Makers, 201535

4Pharmaceuticals & Healthcare, Global, Deal Summary, by Type36

4.1Pharmaceuticals & Healthcare, Global, M&A, 201536

4.1.1Pharmaceuticals & Healthcare, Global, M&A, 2015 by Quarter37

4.1.2Top M&A Deals in 201538

4.1.3Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, 201539

4.2Pharmaceuticals & Healthcare, Global, Equity Offering Deals, 201540

4.2.1Pharmaceuticals & Healthcare, Global, Equity Offering Deals, 2015 by Quarter41

4.2.2Pharmaceuticals & Healthcare, Global, IPO Deals, 201542

4.2.3Top IPOs in 201543

4.2.4Pharmaceuticals & Healthcare, Global, Secondary Offerings Deals, 201544

4.2.5Top Secondary Offerings in 201545

4.2.6Pharmaceuticals & Healthcare, Global, PIPE Deals, 201545

4.2.7Top PIPE Deals in 201546

4.2.8Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, 201547

4.3Pharmaceuticals & Healthcare, Global, Debt Offering Deals, 201548

4.3.1Pharmaceuticals & Healthcare, Global Debt Offerings, 2015 by Quarter49

4.3.2Pharmaceuticals & Healthcare, Global, Public Debt Offerings, 201550

4.3.3Top Public Debt Offerings in 201551

4.3.4Pharmaceuticals & Healthcare, Global, Private Debt Placements, 201551

4.3.5Top Private Debt Placements in 201552

4.3.6Pharmaceuticals & Healthcare, Global, Debt Offering Deals, by Therapy Area, 201553

4.4Pharmaceuticals & Healthcare, Global, Partnership Deals, 201554

4.4.1Pharmaceuticals & Healthcare, Global, Partnership Deals, 2015 by Quarter55

4.4.2Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, 201557

4.4.3Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Value (US$ m), 201558

4.4.4Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), 201559

4.4.5Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, 201560

4.4.6Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), 201561

4.4.7Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), 201563

4.4.8Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, 201564

4.4.9Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, 201565

4.4.10Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, 201565

4.5Pharmaceuticals & Healthcare, Global, Licensing Agreements, 201566

4.5.1Pharmaceuticals & Healthcare, Global, Licensing Agreements, 2015 by Quarter67

4.5.2Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, 201568

4.5.3Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Upfront & Milestone Payments and Deal Value (US$ m), 201569

4.5.4Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), 201570

4.5.5Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), 201571

4.5.6Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), 201572

4.5.7Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), 201574

4.5.8Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Values, 201575

4.5.9Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Upfront Payment, 201576

4.5.10Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Milestone Payment, 201577

4.6Pharmaceuticals & Healthcare, Global, Private Equity Deals, 201578

4.6.1Pharmaceuticals & Healthcare, Global, Private Equity Deals, 2015 by Quarter79

4.6.2Top Private Equity Deals in 201580

4.6.3Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, 201581

4.7Pharmaceuticals & Healthcare, Global, Venture Capital Deals, 201582

4.7.1Pharmaceuticals & Healthcare, Global, Venture Financing Deals, 2015 by Quarter83

4.7.2Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, 201584

4.7.3Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, 201585

4.7.4Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, 201586

4.7.5Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Last One Year87

4.7.6Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, 201588

4.7.7Top Venture Financing Deals in 201590

5Pharmaceuticals & Healthcare, Global, Deal Summary, By Market91

5.1Pharmaceuticals & Healthcare, Global, Oncology Deals, 201591

5.1.1Pharmaceuticals & Healthcare, Global, Oncology Deals, 2015 by Quarter93

5.1.2Oncology – Deals of the Year94

5.2Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, 201598

5.2.1Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, 2015 by Quarter100

5.2.2Central Nervous System – Deals of the Year101

5.3Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, 2015106

5.3.1Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, 2015 by Quarter108

5.3.2Infectious Disease – Deals of the Year109

5.4Pharmaceuticals & Healthcare, Global, Immunology Deals, 2015113

5.4.1Pharmaceuticals & Healthcare, Global, Immunology Deals, 2015 by Quarter115

5.4.2Immunology – Deals of the Year116

5.5Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, 2015119

5.5.1Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, 2015 by Quarter121

5.5.2Cardiovascular – Deals of the Year122

5.6Pharmaceuticals & Healthcare, Global, Metabolic Disorders Deals, 2015125

5.6.1Pharmaceuticals & Healthcare, Global, Metabolic Disorders Deals, 2015 by Quarter127

5.6.2Metabolic Disorders – Deals of the Year128

5.7Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, 2015131

5.7.1Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, 2015 by Quarter133

5.7.2Gastrointestinal – Deals of the Year134

6Pharmaceuticals & Healthcare, Deal Summary, By Geography137

6.1Pharmaceuticals & Healthcare, North America Region, Deals, 2015137

6.1.1Pharmaceuticals & Healthcare, North America Region, Deals, 2015 by Quarter139

6.1.2North America – Deals of the Year140

6.2Pharmaceuticals & Healthcare, European Region Deals, 2015146

6.2.1Pharmaceuticals & Healthcare, Europe, Deals, 2015 by Quarter148

6.2.2Europe – Deals of the Year149

6.3Pharmaceuticals & Healthcare, Asia-Pacific Region, Deals, 2015154

6.3.1Pharmaceuticals & Healthcare, Asia-Pacific Region Deals, 2015 by Quarter156

6.3.2Asia-Pacific – Deals of the Year157

6.4Pharmaceuticals & Healthcare, Rest of the World (ROW) Deals, 2015160

6.4.1Pharmaceuticals & Healthcare, Rest of the World Deals, 2015 by Quarter162

6.4.2Rest of the World – Deals of the Year163

7Pharmaceuticals & Healthcare, Global, Top Financial Advisors166

7.1Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, 2015166

7.2Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, 2015168

8Further Information170

8.1Methodology170

8.2About GlobalData171

8.3Disclosure information171

8.4Disclaimer172

Table

1.1List of Tables

Table 1: Pharmaceutical & Healthcare, Global, Deals Summary, Number of Deals and Deal Value (US$ m), 2011 – 201519

Table 2:Pharmaceuticals & Healthcare, Deals Summary, Global, Number of Deals and Deal Value (US$ m), Q1 2015-Q4 201521

Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), 201523

Table 4: Pharmaceuticals & Healthcare, Top Deals, Global, 201524

Table 5: Pharmaceuticals & Healthcare, Global, Top Deal Makers, Number of Deals and Deal Value (US$ m), 201535

Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), 2011 – 201537

Table 7: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015-Q4 201538

Table 8: Pharmaceuticals & Healthcare, Global, Top M&A Deals, 201538

Table 9: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, 201539

Table 10: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), 2011 – 201541

Table 11: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015-Q4 201542

Table 12: Pharmaceuticals & Healthcare, Global, IPO Deals, Deals Summary, Number of Deals and Deal Value (US$ m), 2011 – 201543

Table 13: Pharmaceuticals & Healthcare, Global, Top IPOs, 201543

Table 14: Pharmaceuticals & Healthcare, Global, Secondary Offerings, Deals Summary, Number of Deals and Deal Value (US$ m), 2011 – 201544

Table 15: Pharmaceuticals & Healthcare, Global, Top Secondary Offerings, 201545

Table 16: Pharmaceuticals & Healthcare, Global, PIPEs, Deals Summary, Number of Deals and Deal Value (US$ m), 2011 – 201546

Table 17: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, 201546

Table 18: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), 201547

Table 19: Pharmaceuticals & Healthcare, Global, Debt Offering, Deals Summary, Number of Deals and Deal Values (US$ m), 2011 – 201548

Table 20: Pharmaceuticals & Healthcare, Global, Debt Offering, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015-Q4 201549

Table 21: Pharmaceuticals & Healthcare, Global, Public Debt Offerings, Deals Summary, Number of Deals and Deal Value (US$ m), 2011 – 201550

Table 22: Pharmaceuticals & Healthcare, Global, Top Public Debt Offerings, 201551

Table 23: Pharmaceuticals & Healthcare, Global, Private Debt Placements, Deals Summary, Number of Deals and Deal Value (US$ m), 2011 – 201552

Table 24: Pharmaceuticals & Healthcare, Global, Top Private Debt Placements, 201552

Table 25: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, Summary, Number of Deals and Deal Values (US$ m), 201553

Table 26: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), 2011 – 201555

Table 27: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q1 2015–Q4 201556

Table 28: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), 201557

Table 29: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payment and Deal Values (US$ m), 201558

Table 30: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), 201560

Table 31: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, 201562

Table 32: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (US$ m), 201564

Table 33: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payment and Deal Values (US$ m), 201564

Table 34: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, 201565

Table 35: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, 201565

Table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), 2011 – 201567

Table 37: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015–Q4 201568

Table 38: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, Number of Deals and Deal Values (US$ m), 201569

Table 39: Pharmaceuticals & Healthcare, Licensing Agreements, Upfront & Milestone Payments and Deal Values (US$ m), 201570

Table 40: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, Upfront & Milestone Payments and Deal Values (US$ m), 201571

Table 41: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q4 2014 – Q4 201573

Table 42: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Upfront & Milestone Payments and Deal Values (US$ m), 201575

Table 43: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payment and Deal Values (US$ m), 201575

Table 44: Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Upfront Payment, 201576

Table 45: Pharmaceutical & Healthcare, Global, Top Licensing Agreements, by Milestone Payment, 201577

Table 46: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), 2011 – 201579

Table 47: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015-Q4 201580

Table 48: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, 201580

Table 49: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$ m), 201581

Table 50: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), 2011 – 201583

Table 51: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015-Q4 201584

Table 52: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), 201585

Table 53: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$ m), 201586

Table 54: Pharmaceutical & Healthcare, Global, Top VC Backed Companies, 201587

Table 55:Pharmaceuticals & Healthcare, Top Venture Financing Firms, Global, Number of Deals and Deal Value (US$ m), 201589

Table 56: Pharmaceuticals & Healthcare, Top Venture Financing Deals, Global, 201590

Table 57: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), 2011 – 201592

Table 58: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015-Q4 201594

Table 59: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), 2011 – 201599

Table 60: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), Q1 2015-Q4 2015101

Table 61: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), 2011 – 2015107

Table 62:Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015-Q4 2015109

Table 63: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), 2011 – 2015114

Table 64: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015-Q4 2015116

Table 65: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), 2011 – 2015120

Table 66: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015-Q4 2015122

Table 67: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), 2011 – 2015126

Table 68: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015-Q4 2015128

Table 69: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), 2011 – 2015132

Table 70: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015-Q4 2015134

Table 71: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Value (US$ m), 2011 – 2015138

Table 72: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Value (US$ m), Q1 2015–Q4 2015140

Table 73: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Value (US$ m), 2011 – 2015147

Table 74: Pharmaceuticals & Healthcare, European Region Deals, Deals Summary, Global, Number of Deals and Deal Value (US$ m), Q1 2015-Q4 2015149

Table 75: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Value (US$ m), 2011 – 2015155

Table 76: Pharmaceuticals & Healthcare, Asia-Pacific Region Deals, Deals Summary, Global, Number of Deals and Deal Value (US$ m), Q1 2015-Q4 2015157

Table 77: Pharmaceuticals & Healthcare, Rest of the World Deals, Deals Summary, Number of Deals and Deal Value (US$ m), 2011 – 2015161

Table 78: Pharmaceuticals & Healthcare, Rest of the World Deals, Deals Summary, Number of Deals and Deal Value (US$ m), Q1 2015–Q4 2015163

Table 79: Pharmaceuticals & Healthcare, Global,, Top Financial Advisors, M&A, Number of Deals and Deal Value (US$ m), 2015167

Table 80:Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Value (US$ m), 2015169

Figures

1.2List of Figures

Figure 1:Pharmaceutical & Healthcare, Global, Number of Deals and Deal Value (US$ m), 2011- 201518

Figure 2:Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Value (US$ m), Q1 2015-Q4 201520

Figure 3:Pharmaceuticals & Healthcare, Global, Number Of Deals (%), 201522

Figure 4:Pharmaceuticals & Healthcare, Global, Deal Values (%), 201523

Figure 5:Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$ m), 2011 – 201536

Figure 6:Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$ m), Q1 2015-Q4 201537

Figure 7:Pharmaceuticals & Healthcare, Global, M&As, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, 201539

Figure 8:Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), 2011 – 201540

Figure 9:Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), Q1 2015-Q4 201541

Figure 10: Pharmaceuticals & Healthcare, Global, IPO Deals, Number of Deals and Deal Value (US$ m), 2011 – 201542

Figure 11: Pharmaceuticals & Healthcare, Global, Secondary Offerings Deals, Number of Deals and Deal Value (US$ m), 2011 – 201544

Figure 12: Pharmaceuticals & Healthcare, Global, PIPE Deals, Number of Deals and Deal Value (US$ m), 2011 – 201545

Figure 13:Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), 201547

Figure 14:Pharmaceuticals & Healthcare, Global, Debt Offering Deals, Number of Deals and Deal Values (US$ m), 2011 – 201548

Figure 15:Pharmaceuticals & Healthcare, Global, Debt Offering Deals, Number of Deals and Deal Values (US$ m), Q1 2015-Q4 201549

Figure 16: Pharmaceuticals & Healthcare, Global, Public Debt Offering Deals, Number of Deals and Deal Value (US$ m), 2011 – 201550

Figure 17: Pharmaceuticals & Healthcare, Global, Private Debt Placements, Number of Deals and Deal Value (US$ m), 2011 – 201551

Figure 18:Pharmaceuticals & Healthcare, Global, Debt Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), 201553

Figure 19:Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), 2011 – 201554

Figure 20:Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q1 2015-Q4 201555

Figure 21:Pharmaceuticals & Healthcare, Global, Partnership Deals Break down (%), 201556

Figure 22:Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), 201557

Figure 23:Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payments and Deal Values (US$ m), 201558

Figure 24: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), 201559

Figure 25:Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, 201560

Figure 26:Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, 201561

Figure 27: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), 201563

Figure 28:Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), 2011 – 201566

Figure 29:Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), Q1 2015-Q4 201567

Figure 30:Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, Number of Deals and Deal Values (US$ m), 201568

Figure 31:Pharmaceuticals & Healthcare, Global, Licensing Agreements, Upfront & Milestone Payments and Deal Values (US$ m), 201569

Figure 32: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), 201570

Figure 33:Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals, 201571

Figure 34:Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Deal Values (US$ m), 201572

Figure 35: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Phase, by Upfront & Milestone Payment and Deal Values (US$ m), 201574

Figure 36:Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), 2011 – 201578

Figure 37:Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), Q1 2015-Q4 201579

Figure 38: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, 201581

Figure 39:Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), 2011 – 201582

Figure 40:Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), Q1 2015-Q4 201583

Figure 41:Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%), 201584

Figure 42:Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Deal Values (%), 201585

Figure 43: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, 201586

Figure 44:Pharmaceuticals & Healthcare, Top Venture Financing Firms, Global, Number of Deals and Deal Value (US$ m), 201588

Figure 45:Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), 2011 – 201591

Figure 46:Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), Q1 2015-Q4 201593

Figure 47:Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), 2015, 2011 – 201598

Figure 48:Pharmaceuticals & Healthcare, Central Nervous System, Number of Deals and Deal Values (US$ m), Q1 2015-Q4 2015100

Figure 49:Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Value (US$ m), 2011 – 2015106

Figure 50:Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Value (US$ m), Q1 2015-Q4 2015108

Figure 51:Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), 2011 – 2015113

Figure 52:Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), Q1 2015-Q4 2015115

Figure 53:Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), 2011 – 2015119

Figure 54:Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), Q1 2015-Q4 2015121

Figure 55:Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), 2011 – 2015125

Figure 56:Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), Q1 2015-Q4 2015127

Figure 57:Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), 2011 – 2015131

Figure 58:Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015-Q4 2015133

Figure 59:Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Value (US$ m), 2011 – 2015137

Figure 60:Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Value (US$ m), Q1 2015–Q4 2015139

Figure 61:Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Value (US$ m), 2011 – 2015146

Figure 62:Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Value (US$ m), Q1 2015–Q4 2015148

Figure 63:Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Value (US$ m), 2011 – 2015154

Figure 64:Pharmaceuticals & Healthcare, Asia-Pacific Region, Deals, Number of Deals and Deal Value (US$ m), Q1 2015–Q4 2015156

Figure 65:Pharmaceuticals & Healthcare, Rest of the World Deals, Number of Deals and Deal Value (US$ m), 2011 – 2015160

Figure 66:Pharmaceuticals & Healthcare, Rest of the World Deals, Number of Deals and Deal Value (US$ m), Q1 2015–Q4 2015162

Figure 67:Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Value (US$ m), 2015166

Figure 68:Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Value (US$ m), 2015168

Frequently asked questions

Partnerships, Licensing, Investments and M&A Deals and Trends for 2015 in Pharmaceuticals thematic reports
Currency USD
$3,500

Can be used by individual purchaser only

$10,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Partnerships, Licensing, Investments and M&A Deals and Trends for 2015 in Pharmaceuticals in real time.

  • Access a live Partnerships, Licensing, Investments and M&A Deals and Trends for 2015 in Pharmaceuticals dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.